Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 6
Submit an article Journal homepage
508
Views
17
CrossRef citations to date
0
Altmetric
Original Articles: Research

The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts

Robyn Marie ScherberDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA; ;Department of Hematology and Oncology, Oregon Health and Science University, Portland, OR, USA; Correspondence[email protected]
,
Holly Lynn GeyerDepartment of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA;
,
Amylou C. DueckDepartment of Biostatistics, Mayo Clinic, Scottsdale, AZ, USA;
,
Heidi E. KosiorekDepartment of Biostatistics, Mayo Clinic, Scottsdale, AZ, USA;
,
Guido FinazziUnit of Hematology, Ospedale Papa Giovanni XXIII, Foundation for Research (FROM), Bergamo, Italy;
,
Riccardo CavazzinaConsorzio Mario Negri Sud, Santa Maria Imbaro (CH), Italy;
,
Arianna MasciulliIstituto Mario Negri Sud, S. Maria Imbaro, Italy;
,
Marco ScaranoIstituto Mario Negri Sud, S. Maria Imbaro, Italy;
,
Alessandro M. VannucchiSection of Hematology, University of Florence, Florence, Italy
,
Ruben A. MesaDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA;
&
Tiziano BarbuiUnit of Hematology, Ospedale Papa Giovanni XXIII, Foundation for Research (FROM), Bergamo, Italy;
show all
Pages 1481-1487 | Received 11 May 2016, Accepted 03 Oct 2016, Published online: 10 Nov 2016

References

  • Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723–1735.
  • Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol. 2006;19:617–633.
  • Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68–76.
  • Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272–4290.
  • Passamonti F. How I treat polycythemia vera. Blood. 2012;120:275–284.
  • Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.
  • Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098–4103.
  • Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401–408.
  • Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186–1196.
  • Scherber R, Dueck A, Mesa R. Symptoms, risk classification, and spleen size in JAK2 inhibitor naive myelofibrosis: implications for JAK2 inhibitor treatment. EHA Learning Center; 2016. a132894.
  • Geyer H, Scherber R, Kosiorek H, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. J Clin Oncol. 2016;34:151–159.
  • Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239–252.
  • Hunt JR, Zito CA, Johnson LK. Body iron excretion by healthy men and women. Am J Clin Nutr. 2009;89:1792–1798.
  • Tobiasson M, Alyass B, Soderlund S, et al. High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio. Med Oncol. 2010;27:105–107.
  • FDA news release. FDA approves Jakafi to treat patients with a chronic type of bone marrow disease. 2014. [Internet]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425677.htm.
  • Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood. 2014;124:3529–3537.
  • Barbui T, Finazzi G. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost. 2007;33:321–329.
  • Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120:513–520.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.